Follow @TheHPRA
Contact us
As Gaeilge
My HPRA:
Login
Register
About Us
Medicines
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Medicines
Safety Notices
My HPRA:
Login
Register
About Us
Medicines
COVID-19 vaccines and treatments
Our Role
Medicines Information
Safety Information
Safety Notices
Quality Information
Regulatory Information
News & Events
Special Topics
Emergency Medicines
Emergency Contact Details
Veterinary
Medical Devices
Cosmetics
Controlled Substances
Blood, Tissues, Organs
Adempas (riociguat) - Important Safety Infomation from Bayer Pharma AG and MSD as approved by the HPRA
Notice type:
3rd Party Publications
Date:
07/07/2016
Problem Or Issue:
Important Safety Information communication from Bayer Pharma AG and MSD on Adempas (riociguat): New contraindication in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP).
Important Safety Information - Adempas (riociguat)
« Back
Date Printed: 25/04/2024